Collaborative causal inference on distributed data

The development of technologies for causal inference with the privacy preservation of distributed data has attracted considerable attention in recent years. To address this issue, we propose a data collaboration quasi-experiment (DC-QE) that enables causal inference from distributed data with privacy preservation. In our method, first, local parties construct dimensionality-reduced intermediate representations from the private data. Second, they share intermediate representations, instead of private data for privacy preservation. Third, propensity scores were estimated from the shared intermediate representations. Finally, the treatment effects were estimated from propensity scores. Our method can reduce both random errors and biases, whereas existing methods can only reduce random errors in the estimation of treatment effects. Through numerical experiments on both artificial and real-world data, we confirmed that our method can lead to better estimation results than individual analyses. Dimensionality-reduction loses some of the information in the private data and causes performance degradation. However, we observed that in the experiments, sharing intermediate representations with many parties to resolve the lack of subjects and covariates, our method improved performance enough to overcome the degradation caused by dimensionality-reduction. With the spread of our method, intermediate representations can be published as open data to help researchers find causalities and accumulated as a knowledge base.Comment: 14 pages, 4 figure

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. METHODS: Patients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study. RESULTS: A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1-4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected. CONCLUSION: Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population. CLINICALTRIALSGOV IDENTIFIER: REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo

Minimal Symptom Expression' in Patients With Acetylcholine Receptor Antibody-Positive Refractory Generalized Myasthenia Gravis Treated With Eculizumab

The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia gravis (gMG), and its open-label extension

Dai Toa zeniki chizu [cartographic material] /

Map of East and Southeast Asia and Australia showing geographical features, Japanese embassies and consulates, petroleum oil producing areas, borders, capitals and cities, canals, railways, Japanese ship routes, other ship routes, undersea cables, wireless stations, light houses, and military transport routes for USA, Britain and Russia, which they used to suppport the Republic of China. Also shows ecological zones: New Wallace Line, Wallace Line, West Wallace Line and Weber's Line. Relief shown by contours, shading and spot heights.; Heights above sea leave are shown in 8 levels with different colours; depth of the sea is recorded in five levels.; Also available online http://nla.gov.au/nla.map-vn2486139; NLA copy has note m36025/516, 23.3.77 written on the top. 880-05 First inset. Taiheiyo.[ = Pacific Ocean]. Scale at the equator 1:40,000,000 -- Second inset. Hawai Shoto [ = Hawaiian Islands]. Scale 1:1,800,000 -- Third inset. Shinju-wan fukin [ = Pearl Harbor vicinity]. Scale 1:150,000